抗体-放射性核素偶联物靶向成纤维细胞活化蛋白用于癌症治疗
本研究以sibrotuzumab衍生物制备抗成纤维细胞活化蛋白(FAP)抗体PKU525,用89Zr标记行PET成像评估药代动力学与阻断实验,用177Lu标记行SPECT成像、离体生物分布及放疗研究。结果显示肿瘤摄取快速、高且选择性好,3.7 MBq即可完全抑制荷瘤小鼠肿瘤生长且未见明显副作用。
要点
- 89Zr标记PKU525的肿瘤摄取在192 h达峰值SUVmax=18.4±2.3(n=4),血液、肝等快速清除。
- 177Lu标记PKU525在24、96、168、240 h的肿瘤摄取分别为23.04±5.11、33.2±6.36、19.87±6.84、19.02±5.90%ID/g(n=5)。
- 3.7 MBq多剂量177Lu标记PKU525可完全抑制小鼠肿瘤生长,未见可观察到的副作用。
核心结论
- 研究开发并体外体内评价了一种靶向FAP的抗体-放射性核素偶联物PKU525,其在荷瘤小鼠中肿瘤摄取快速且高、背景干净,显著抑制肿瘤而副作用几乎可忽略,作者认为其有望进一步开展临床转化研究。
研究设计与样本
- 以sibrotuzumab衍生物制备抗FAP抗体PKU525,用89Zr标记行PET成像进行药代动力学与阻断研究,筛选偶联策略并用177Lu标记行SPECT成像,在荷HT-1080-FAP肿瘤的NU/NU小鼠中行177Lu标记抗体的生物分布与放疗研究。
主要发现
- 多时间点PET成像显示[89Zr]Zr-DFO-PKU525的肿瘤蓄积强烈、选择性好且相对快速,时间-活度曲线显示肿瘤摄取持续增加至192 h达最高摄取(SUVmax=18.4±2.3,n=4)后逐渐下降。
- 放射性从血液、肝脏及其他主要器官快速清除,产生高肿瘤-本底比;体内阻断实验提示[89Zr]Zr-DFO-PKU525具有FAP特异性,FAP阴性肿瘤摄取几乎可忽略。
- 离体生物分布显示[177Lu]Lu-DOTA-NCS-PKU525在注射后24、96、168、240 h的肿瘤摄取分别为23.04±5.11、33.2±6.36、19.87±6.84、19.02±5.90%ID/g(n=5),与PET成像一致。
- 治疗实验中测试了多剂量[177Lu]Lu-DOTA-NCS-PKU525,数据提示3.7 MBq可能足以完全抑制小鼠肿瘤生长且未显示可观察到的副作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Fibroblast activation protein is one of the most attractive targets for tumor diagnosis and therapy. There have been many successful clinical translations with small molecules and peptides, yet only a few anti-FAP antibody diagnostic or therapeutic agents have been reported. Antibodies often feature good tumor selectivity and long tumor retention, which may be a better-match with therapeutic radionuclides (e.g.,177Lu, 225Ac) for cancer therapy. Here we report a 177Lu-labeled anti-FAP antibody, PKU525, as a therapeutic radiopharmaceutical for FAP-targeted radiotherapy. METHODS: The anti-FAP antibody is produced as a derivative of sibrotuzumab. The pharmacokinetics and blocking study are performed with 89Zr-labeled antibody by PET imaging. The conjugation strategies have been screened and tested with SPECT imaging through 177Lu-labeling. The biodistribution and radiotherapy studies are performed on 177Lu-labeled anti-FAP antibody in NU/NU mice-bearing HT-1080-FAP tumors. RESULTS: A multiple time-point PET imaging study shows that the tumor accumulation of [89Zr]Zr-DFO-PKU525 is intense, selective, and relatively rapid. The time activity curve indicates that the tumor uptake continually increases until reaches the highest uptake (SUVmax = 18.4 ± 2.3, n = 4) at 192 h, then gradually declines. Radioactivity rapidly cleared from the blood, liver, and other major organs, resulting in high tumor-to-background ratios. An in vivo blocking experiment suggests that [89Zr]Zr-DFO-PKU525 is FAP-specific and the uptake in FAP-negative tumors is almost negligible. Ex vivo biodistribution study shows that the tumor uptake of [177Lu]Lu-DOTA-NCS-PKU525 is 23.04 ± 5.11% ID/g, 33.2 ± 6.36% ID/g, 19.87 ± 6.84% ID/g and 19.02 ± 5.90% ID/g at 24 h, 96 h, 168 h, and 240 h after injection (n = 5), which is corroborated with the PET imaging. In therapeutic assays, multiple doses of [177Lu]Lu-DOTA-NCS-PKU525 have been tested in tumor-bearing mice, and the data suggests that 3.7 MBq may be sufficient to completely suppress the tumor growth in mice without showing observable side effects. CONCLUSION: A FAP-targeted antibody-radionuclide conjugate was developed and evaluated in vitro and in vivo. Its tumor accumulation is rapid and high with a clean background. It remarkably suppresses the tumors in mice while the side effect is almost negligible, showing that it is promising for further clinical translational studies.
引用
- Xu M, Chen J, Zhang P, et al. An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy. Eur J Nucl Med Mol Imaging. 2023. PMID: 37318538. doi:10.1007/s00259-023-06300-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。